Scott Platshon
Scott Platshon serves as the Chief Business Officer of Zymeworks, Inc., where he is responsible for driving the company's business development strategies. He recently highlighted the potential financial gains from the acquisition of Theravance Biopharma, particularly in relation to royalties from the respiratory drug Yupelri and other future sales milestones.
Global Media Ratings
Countries Mentioned
No country-level mention data available.
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Canada:
Scott Platshon, chief business officer of Zymeworks, shared details about the potential financial benefits of the Theravance acquisition.
7